/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Metastatic Bladder Cancer — Rapid Case Review Issue 8
Metastatic Bladder Cancer — Rapid Case Review Issue 8

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos · Sep 16, 2026

Experts review metastatic bladder cancer cases, discussing toxicity management for EV+pembro/erdafitinib & tailoring therapy for unique patients.

GLP-1 Inhibitors May Improve Enfortumab Vedotin-Induced Neuropathy in Diabetic Patients

Beyond managing hyperglycemia, GLP-1 inhibitors have been observed to improve neuropathy in diabetic patients receiving Enfortumab Vedotin (EV). This suggests a dual benefit, challenging the assumption that EV is the sole cause of worsening neuropathy in this population.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago

Oncologists Can Frame Enfortumab Vedotin-Induced Rash as a Positive Predictor of Response

To improve patient morale and adherence, clinicians can frame the development of a rash from enfortumab vedotin (EV) as a positive sign. Patients who develop this side effect are known to have better treatment responses, turning a negative experience into an encouraging one.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago

On-Body Glucose Monitors Offer Superior Toxicity Management for Hyperglycemic Cancer Drugs

Continuous on-body glucose monitors provide granular, real-time data that is far more valuable than periodic A1C or fasting glucose tests. This allows for precise management of toxicities like hyperglycemia and neuropathy caused by drugs like Enfortumab Vedotin or AKT inhibitors.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago

Routine Lynch Syndrome Testing is Warranted for All Upper Tract Urothelial Cancer Patients

Clinicians should test all patients with upper tract urothelial cancer for Lynch syndrome, regardless of age. The condition is surprisingly prevalent in this rare cancer, and a diagnosis can fundamentally alter treatment by making patients prime candidates for highly effective immune checkpoint inhibitors.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago

Delayed Skin Toxicity from Prior Immunotherapy Can Mimic Enfortumab Vedotin Side Effects

When a patient on enfortumab vedotin (EV) develops a severe rash, clinicians must consider delayed toxicity from a prior checkpoint inhibitor (ICI). Immune effects like pemphigoid can manifest months after stopping an ICI, requiring different management and potentially precluding EV re-challenge.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago

Re-challenge with Combination IO is Viable for Relapse on Adjuvant Immunotherapy

For patients who relapse on adjuvant nivolumab without prior immune-mediated toxicity, clinicians should consider treatment with enfortumab vedotin plus pembrolizumab. The synergy from EV's cell-killing mechanism may re-awaken the immune system, making the combination more effective than EV alone.

Metastatic Bladder Cancer — Rapid Case Review Issue 8 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Research To Practice | Oncology Videos·2 months ago